Clinical Significance of Half-lives of Tumor Markers α-fetoprotein and Des-γ-carboxy Prothrombin After Hepatectomy for Hepatocellular Carcinoma
Overview
Authors
Affiliations
Aim: The prognostic significance of the half-lives (HLs) of α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) in patients undergoing hepatectomy for hepatocellular carcinoma (HCC) is unclear. We evaluated the HLs of AFP and DCP in a cohort of such patients.
Methods: This study included data on 202 patients with HCC who underwent curative hepatectomy and had preoperative AFP concentrations ≥100 ng/mL or DCP ≥200 mAU/mL. We calculated the HLs of AFP and DCP from their values just before and 1 month after hepatectomy. We identified three groups: a normalization group, tumor marker concentrations within normal range 1 month post-hepatectomy; a long group, HL of AFP ≥7 days or DCP ≥4 days; and a short group, remaining patients. We evaluated associations between HL and prognosis.
Results: Three-year recurrence-free survival (RFS) in the normalization (n = 70), short (n = 71), and long groups (n = 61) was 41.3%, 46.0%, and 16.8%, respectively (P = 0.002). Five-year overall survival (OS) of normalization, short, and long groups was 72.6, 70.6 and 43.8%, respectively (P = 0.002). Multivariate analysis revealed that long HL is an independent risk factor for poor RFS (hazard ratio [HR] 2.21, P = 0.0006) and poor OS (HR 2.70, P = 0.004). The extrahepatic recurrence rate was 21.3% (13/61) in the long group, which is higher than in the normalization group (8.6%, 6/70) (P = 0.04) and short group (9.9%, 7/71) (P = 0.07).
Conclusion: Post-hepatectomy HLs of AFP and DCP are predictors of long-term outcome in patients with HCC.
Des-γ-carboxy Prothrombin in hepatocellular carcinoma post-operative recurrence risk evaluation.
Pan X, Zhou Y, Li Z, Guo P, Zeng J, Dong X Commun Med (Lond). 2025; 5(1):65.
PMID: 40050645 PMC: 11885828. DOI: 10.1038/s43856-025-00784-z.
Wang M, Qian G, Xiao H, Liu X, Sun L, Chen Z Oncologist. 2024; 29(12):e1723-e1733.
PMID: 38907676 PMC: 11630741. DOI: 10.1093/oncolo/oyae139.
Xing X, Cai L, Ouyang J, Wang F, Li Z, Liu M Nat Commun. 2023; 14(1):8392.
PMID: 38110372 PMC: 10728065. DOI: 10.1038/s41467-023-44255-2.
Yao C, Wang J, Chen C, Hung C, Yen Y, Kee K Diagnostics (Basel). 2023; 13(4).
PMID: 36832184 PMC: 9955975. DOI: 10.3390/diagnostics13040696.
Byun D, Lee S, Kim H, You Y, Jung J, Jang J Ann Surg Treat Res. 2022; 103(5):271-279.
PMID: 36452307 PMC: 9678661. DOI: 10.4174/astr.2022.103.5.271.